Versatile News at Street: Facebook, Inc. (NASDAQ:FB), Legg Mason Inc. (NYSE:LM), Blueprint Medicines Corporation (NASDAQ:BPMC)


Facebook, Inc. (NASDAQ:FB) rose over 2.44% in previous trading session as its program inspires young girls to try cybersecurity careers. The cybersecurity field is in great required of more talent as well as one way of filling this required is to build a pipeline of support starting at a younger age, since many girls drop off from STEM interests around 12 or 13, some tech companies believe. In particular, there’s a lack of women in technical security roles. In its latest effort, Facebook Inc. hopes to inspire more girls to pursue these types of careers before they even get into high school through efforts targeted at underserved students in the San Jose area. “We need more people to do this (work),” Alex Stamos, Facebook’s chief security officer, told the girls Friday afternoon. “It’s very hard to find people to hire. The need outstrips talent.” Facebook, Inc. (NASDAQ:FB) begun last trade with a price of $88.68 and throughout the trading session climbed at a high of $90.22. The day-trade ended with 2.44% to $90.10. The stock is going forward to its 52-week low with 39.06% and lagging behind from its 52-week high price with 0.78%. FB last month stock price volatility remained 1.80%.

Legg Mason Inc. (NYSE:LM) released that its preliminary assets under management of $699.2B as of June 30, 2015. The latest-month’s AUM comprises preliminary long-term outflows of $0.5 billion, reflecting equity outflows of $0.5 billion. Liquidity inflows were $1.1 billion. This month’s AUM included $1.5 billion in positive foreign exchange impact. Legg Mason Inc. (NYSE:LM) stock price closed at $49.36 with the total traded volume of 1.73 Million shares. Its price to sales ratio ended at 1.94. Its market capitalization is 5.47 Billion. The stock owned by the Financial Institutions was 87.10% while by insiders was 0.60%.

Blueprint Medicines Corporation (NASDAQ:BPMC) released on Monday that U.S. Food and Drug Administration accepted the firm’s Investigational New Drug apps to begin Phase 1 clinical trials for its two lead drug candidates: BLU-554 as well as BLU-285. BLU-554 is for the treatment of advanced hepatocellular carcinoma or HCC and cholangiocarcinoma, and BLU-285 is for unresectable, treatment-resistant gastrointestinal stromal tumor or GIST. BLU-554 is a potent and selective inhibitor of fibroblast growth factor receptor 4 or FGFR4. Aberrant signaling of FGFR4 is a disease driver in up to 30 percent of HCC patients. It may also play a role in a subset of patients with cholangiocarcinoma, a related cancer of the biliary duct. BLU-285 is a potent and selective inhibitor of KIT Exon 17 and PDGFR-alpha D842V mutants, which are key disease drivers of metastatic and treatment-resistant GIST, which is the most common form of sarcoma of the gastrointestinal tract. Blueprint Medicines Corporation (NASDAQ:BPMC) has the market capitalization of 721.32 Million. Shares of firm moved up 3.50% to close at $29.00 with the total traded volume of 207807. The firm has current ratio of 3.60 for the most recent quarter.

author avatar
Jason Dinner